BioCryst takes legal action to defend rare genetic drug patent; shares fall

BioCryst Pharmaceuticals

11/03/2025 14:39

** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O fall 2% to $7.24

** BCRX on Monday filed lawsuit against Annora Pharma and other companies for patent infringement, according to SEC filing

** BCRX is seeking to stop the companies from making generic version of its rare genetic drug, Orladeyo, and delay U.S. FDA approval until patents expire

** Annora claims the three patents that expire in 2039 are invalid, unenforceable and/or won't be infringed by their generic product

** Annora did not immediately respond to Reuters' request for comment

** BCRX gained ~24% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))